Preliminary results of a phase II study to evaluate gefitinib (ZD1839) combined with paclitaxel (P) and carboplatin (C) as second-line therapy in patients (pts) with ovarian carcinoma (OC) Conclusions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results